BR112012004862A2 - método para a preparação de um composto , duloxetina cristalina, e, composição farmacêutica - Google Patents

método para a preparação de um composto , duloxetina cristalina, e, composição farmacêutica

Info

Publication number
BR112012004862A2
BR112012004862A2 BR112012004862A BR112012004862A BR112012004862A2 BR 112012004862 A2 BR112012004862 A2 BR 112012004862A2 BR 112012004862 A BR112012004862 A BR 112012004862A BR 112012004862 A BR112012004862 A BR 112012004862A BR 112012004862 A2 BR112012004862 A2 BR 112012004862A2
Authority
BR
Brazil
Prior art keywords
compound
preparation
pharmaceutical composition
crystalline duloxetine
duloxetine
Prior art date
Application number
BR112012004862A
Other languages
English (en)
Portuguese (pt)
Inventor
Hana Brusová
Josef Cinibulk
Ludek Ridvan
Veronika Grüwaldová
Original Assignee
Zentiva Ks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva Ks filed Critical Zentiva Ks
Publication of BR112012004862A2 publication Critical patent/BR112012004862A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
BR112012004862A 2009-09-02 2010-09-02 método para a preparação de um composto , duloxetina cristalina, e, composição farmacêutica BR112012004862A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2009-584A CZ304602B6 (cs) 2009-09-02 2009-09-02 Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)
PCT/CZ2010/000099 WO2011026449A1 (en) 2009-09-02 2010-09-02 A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine)

Publications (1)

Publication Number Publication Date
BR112012004862A2 true BR112012004862A2 (pt) 2015-09-08

Family

ID=43413356

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004862A BR112012004862A2 (pt) 2009-09-02 2010-09-02 método para a preparação de um composto , duloxetina cristalina, e, composição farmacêutica

Country Status (11)

Country Link
EP (1) EP2473497A1 (cs)
JP (1) JP2013503823A (cs)
KR (1) KR20120047262A (cs)
CN (1) CN102482254A (cs)
BR (1) BR112012004862A2 (cs)
CZ (1) CZ304602B6 (cs)
EA (1) EA021528B1 (cs)
IL (1) IL218329A0 (cs)
MX (1) MX2012002621A (cs)
WO (1) WO2011026449A1 (cs)
ZA (1) ZA201201570B (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626735A (zh) * 2012-08-28 2014-03-12 石药集团中奇制药技术（石家庄）有限公司 一种盐酸度洛西汀晶型及其制备方法
CN104478849A (zh) * 2014-02-14 2015-04-01 广东东阳光药业有限公司 制备去甲肾上腺素再摄取双重抑制剂的方法
CN106265528A (zh) * 2015-05-12 2017-01-04 法德生技药品股份有限公司 制备药物凝集体的方法
JP2016222628A (ja) * 2015-06-03 2016-12-28 株式会社トクヤマ デュロキセチン塩酸塩の製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880007433A (ko) 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
DE10212301A1 (de) 2002-03-20 2003-10-02 Bayer Ag Verfahren zur Herstellung von Aryl-aminopropanolen
PT1539673E (pt) 2002-07-09 2007-11-14 Lonza Ag Processo para preparação de beta-aminoálcoois nmonossubstituídos
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
CZ297560B6 (cs) 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
US7534900B2 (en) * 2005-03-14 2009-05-19 Teva Pharmaceutical Industries Ltd Process for the purification of duloxetine hydrochloride
EP1820800A1 (en) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Crystalline forms of duloxetine hydrochloride and processes for their preparation
GB0612508D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
GB0612509D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
CZ300116B6 (cs) * 2006-12-05 2009-02-11 Zentiva, A. S. Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
US8269023B2 (en) * 2007-03-05 2012-09-18 Lupin Ltd. Process for preparation of duloxetine hydrochloride

Also Published As

Publication number Publication date
EA201290127A1 (ru) 2013-02-28
MX2012002621A (es) 2012-07-03
IL218329A0 (en) 2012-04-30
JP2013503823A (ja) 2013-02-04
CZ304602B6 (cs) 2014-07-30
CN102482254A (zh) 2012-05-30
ZA201201570B (en) 2013-08-28
KR20120047262A (ko) 2012-05-11
CZ2009584A3 (cs) 2011-03-09
EP2473497A1 (en) 2012-07-11
EA021528B1 (ru) 2015-07-30
WO2011026449A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
BRPI0909691A2 (pt) Composto, método para preparar um composto, e, composição farmacêutica
BRPI1011764A2 (pt) composição farmacêutica, e, método para preparar uma composição farmacêutica
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0817423A2 (pt) Processos para a preparação de um composto, para a preparação de uma formulação farmacêutica, e para a preparação de um intermediário de um composto, e, composto
BR112014007645A2 (pt) composto heterocíclico, métodos para a preparação de um composto heterocíclico, e, composição farmacêutica
BRPI0917196A2 (pt) método para a preparação de um complexo, e, forma cristalina de um composto.
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
BRPI0918971A2 (pt) tienopirimidinas para composições farmacêuticas
BRPI0922566A2 (pt) polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
BRPI1010933A2 (pt) processo para a preparação de um pó, e, composto
BRPI0906475A2 (pt) Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto
BRPI1016132A2 (pt) composição, formulação farmacêutica, método para fabricar uma formulação farmacêutica estável.
BRPI0613574A2 (pt) forma cristalina isolada de um composto, método para preparar um composto, e, composição farmacêutica
BR112012002102A2 (pt) composição farmaceutica e metodo para preparar uma composição farmaceutica
BR112013008008A2 (pt) composto, composição farmacêutica e processo para preparar um composto
BRPI1012978A2 (pt) composição tópica, método para preparar a mesma, e, uso de um composto
BR112012004173A2 (pt) "composto, composição, método para preparar uma composição, e, uso de um composto"
BRPI0922173A2 (pt) preparação farmacêutica, e, método para preparar uma preparação farmacêutica
BRPI1007624A2 (pt) composto, método para preparar uma composição, composto ou sal farmaceuticamente aceitável deste e uso de um composto ou um sal farmaceuticamente aceitável deste
BRPI1007161A2 (pt) composição farmacêutica oral, e processo para preparar uma composição
BRPI0814163A2 (pt) Processo para a preparação de compostos, forma cristalina, e, composição farmacêutica
BRPI0918955A2 (pt) preparação sólida, e, método para estabilizar um composto, e para melhorar a dissoulução de um composto
BRPI1007186A2 (pt) composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.